FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0.02 (0.403%)
Latest TSVT News
Danny Green
Mar 19, 2025
2seventy bio, Inc. (NASDAQ:TSVT) Sees Positive Analyst Sentiment and Financial Growth
2seventy bio, Inc. (NASDAQ:TSVT) is a biotechnology company based in Cambridge, Massachusetts, specializing in cell and gene therapies for cancer treatment. The company is known for its CAR-T cell product candidates and has a significant collaboration with Bristol-Myers Squibb Company. This partnership is crucial for advancing their pipeline and enhancing their market presence. The consensus price target for TSVT has seen a notable increase over the past year, rising from $3.5 to $5. This upwar...
Stuart Mooney
Mar 17, 2025
2seventy bio, Inc. (NASDAQ:TSVT) Earnings Outlook and Financial Analysis
2seventy bio, Inc. (NASDAQ:TSVT) is preparing to announce its quarterly earnings on March 18, 2025. Analysts expect the company to report an earnings per share (EPS) of -$0.20 and revenue of about $13 million. Despite these projections, the company has recently been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings potential. The Zacks Rank upgrade suggests that TSVT's stock might see upward movement soon. This ranking system is based on a company's evolving earni...
Tony Dante
Nov 12, 2024
2Seventy Bio Inc. (NASDAQ:TSVT) Faces Challenges Amid Competitive Landscape
2Seventy Bio Inc. (NASDAQ:TSVT) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company operates in a competitive landscape, with peers like Bluebird Bio and CRISPR Therapeutics. On November 12, 2024, Goldman Sachs reiterated its "Sell" rating for TSVT, maintaining a "hold" action, with the stock priced at approximately $4.31, as highlighted by StreetInsider. During its Q3 2024 earnings call, 2Seventy Bio reported a quarterly loss of $0.18 per sha...
Seeking Alpha
Aug 11, 2024
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs William Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmannn - Chief Medical Officer Conference Call Participants Daina Graybosch - Leerink Kelsey Goodwin - Guggenheim Securities Operator Good day, and thank you for standing by. Welcome to the 2Seventy Bio Second Quarter 2024 Earnings Con...
Zacks Investment Research
Aug 7, 2024
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.83 per share a year ago.
Zacks Investment Research
Aug 5, 2024
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.
Zacks Investment Research
Aug 5, 2024
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Alpha
Jul 9, 2024
2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition
2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk. Abecma shows favorable clinical data but faces strong competition from Carvykti.
InvestorPlace
Jul 5, 2024
3 Hidden Stock Gems That Wall Street Is Overlooking
No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made.
Zacks Investment Research
May 8, 2024
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.08 per share a year ago.
